LGD-4033 is a potent, selective androgen receptor modulator that has been designed to treat subjects [§2 - T.O.U.] who suffer from muscle wasting diseases by elevating lean muscle mass [§2 - T.O.U.].
GW501516 is a potent PPARβ (peroxisome proliferator-activated receptor) agonist that exhibits 1,000-fold more selectivity than existing subtypes and has been shown to regulate gene expression in lipid catabolism.
The MK-2866 selective androgen receptor modulator (GTx-024) selectively targets muscle cells with an affinity of 3.8 nM and exhibits (research suggests) the ability to increase lean body mass, decrease fat deposition, and improve bone density among subjects [§2 - T.O.U.] in good physical condition.
MK-677 is a drug that mimics growth hormone [§2 - T.O.U.] by binding to and activating the ghrelin receptor (i.e, ghrelin receptor agonist). This particular compound has been ostensibly called the "holy grail of aging research." [§2 - T.O.U.]
RAD140 is an orally available, non-steroidal [§2 - T.O.U.] SARM that is the subject of ongoing preclinical and clinical studies, designed to artificially augment testosterone [§2 - T.O.U.] (particularly in low-T patients [§2 - T.O.U.]) in an effort to increase androgen-responsive tissues.
